Biomarkers, Clinical Course, and Individual Needs in COPD Patients in Primary Care: The Study Protocol of the Stockholm COPD Inflammation Cohort (SCOPIC)

Background To facilitate effective personalized medicine, primary health care needs better methods of assessing and monitoring chronic obstructive pulmonary disease (COPD). Aim This cohort study aims to investigate how biomarkers relate to clinical characteristics and COPD patients’ subjective needs over time. Methods Patients (n=750) in different COPD severity according to the GOLD criteria and age- and sex-matched controls (n=750) will be recruited over a period of 5 years from 15 primary health care centers in Region Stockholm, Sweden, and followed for 10 years in the first instance. Data on patients’ subjective needs will be collected via telephone/email, data on clinical/physiological variables (eg, symptoms, exacerbations, comorbidities, medications, smoking habits, lung function) from existing databases that are based on medical records, and data on biomarkers via repeated blood sampling. Quantitative and qualitative methods will be used. Initial results are expected after 2 years (feasibility test), and a larger body of evidence after 5 years. Discussion The study is expected to provide definitive and clinically useful scientific evidence about how biomarkers relate to clinical variables and patients’ subjective needs. This new evidence will facilitate accurate, and personalized COPD management by the use of valid biomarkers. It will provide useful tools for primary care professionals and may facilitate optimal self-management.

[1]  M. Miravitlles,et al.  [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. , 2022, Archivos de bronconeumologia.

[2]  A. Lindén,et al.  Occupational exposure to particles and increased risk of developing chronic obstructive pulmonary disease (COPD): A population-based cohort study in Stockholm, Sweden. , 2021, Environmental research.

[3]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD. , 2021, Archivos de bronconeumologia.

[4]  J. Lötvall,et al.  Decreased COPD prevalence in Sweden after decades of decrease in smoking , 2020, Respiratory Research.

[5]  L. Fairclough,et al.  The role of CD8 + T lymphocytes in chronic obstructive pulmonary disease: a systematic review , 2020, Inflammation research : official journal of the European Histamine Research Society ... [et al.].

[6]  A. Lindén,et al.  Increased MUC1 plus a larger quantity and complex size for MUC5AC in the peripheral airway lumen of long-term tobacco smokers. , 2020, Clinical science.

[7]  Min Li,et al.  Reduced Serum Concentration of CC16 Is Associated with Severity of Chronic Obstructive Pulmonary Disease and Contributes to the Diagnosis and Assessment of the Disease , 2020, International journal of chronic obstructive pulmonary disease.

[8]  A. Nager,et al.  COPD patients need more information about self-management: a cross-sectional study in Swedish primary care , 2019, Scandinavian journal of primary health care.

[9]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[10]  S. Wong,et al.  Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis , 2017, Scientific Reports.

[11]  G. Ciprandi,et al.  Inflammatory biomarkers for asthma endotyping and consequent personalized therapy , 2017, Expert review of clinical immunology.

[12]  Laura Fratiglioni,et al.  Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  A. Bossios,et al.  Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD , 2016, International journal of chronic obstructive pulmonary disease.

[14]  A. Lindén,et al.  Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.

[15]  G. Wesseling,et al.  Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco Smoking , 2015, Respiration.

[16]  A. Lindén,et al.  Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization? , 2015, International journal of chronic obstructive pulmonary disease.

[17]  K. Larsson,et al.  Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. , 2014, Respiratory medicine.

[18]  N. Zwar,et al.  Patients’ perspectives on the impact of a new COPD diagnosis in the face of multimorbidity: a qualitative study , 2014, npj Primary Care Respiratory Medicine.

[19]  Å. Wheelock,et al.  Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction. , 2014, Chest.

[20]  P. Frith,et al.  Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[21]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[22]  L. Törnkvist,et al.  The process of trying to quit smoking from the perspective of patients with chronic obstructive pulmonary disease. , 2012, Scandinavian journal of caring sciences.

[23]  B. Fischer,et al.  Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation , 2011, International journal of chronic obstructive pulmonary disease.

[24]  A. Bossios,et al.  Effects of tobacco smoke on IL-16 in CD8+ cells from human airways and blood: a key role for oxygen free radicals? , 2011, American journal of physiology. Lung cellular and molecular physiology.

[25]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[26]  T. Louis,et al.  Eosinophil and T cell markers predict functional decline in COPD patients , 2009, Respiratory research.

[27]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[28]  S. Duncan,et al.  Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease , 2008, International journal of chronic obstructive pulmonary disease.

[29]  M. Hyland,et al.  Educational impact of pulmonary rehabilitation: Lung Information Needs Questionnaire. , 2008, Respiratory medicine.

[30]  Helvi Kyngäs,et al.  The qualitative content analysis process. , 2008, Journal of advanced nursing.

[31]  S. Hodge,et al.  Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects , 2007, Clinical and experimental immunology.

[32]  N. McElvaney,et al.  The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses. , 2007, Biochemical Society transactions.

[33]  R. Perng,et al.  Inhaled Fluticasone and Salmeterol Suppress Eosinophilic Airway Inflammation in Chronic Obstructive Pulmonary Disease: Relations with Lung Function and Bronchodilator Reversibility , 2006, Lung.

[34]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[35]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[36]  Bernard,et al.  Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[38]  A. Bernard,et al.  Decrease of serum Clara cell protein in smokers , 1992, The Lancet.

[39]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[40]  J. Fawcett,et al.  The metaparadigm of nursing: present status and future refinements. , 1984, Image--the journal of nursing scholarship.